Drug reference
DUOFILM ® Plantar and mosaic warts ▶TO THE LESION ▶Adult: Apply daily, treatment may need to be continued for up to 3 months SALACTOL ® Warts, particularly plantar warts | Verrucas | Corns | Calluses ▶TO THE LESION ▶Adult: Apply daily, treatment may need to be continued for up to 3 months SALATAC ® Skin Warts | Verrucas | Corns | Calluses ▶TO THE LESION ▶Adult: Apply daily, treatment may need to be continued for up to 3 months
PDF page 1375
Preparation of salicylic acid in a collodion basis (Salactol ®) is available but some patients may develop an allergy to colophony in the formulation.
PDF page 1375
There can be variation in the licensing of different medicines containing the same drug. Paint CAUTIONARY AND ADVISORY LABELS 15 ▶Duofilm (GlaxoSmithKline Consumer Healthcare) Lactic acid 150 mg per 1 gram, Salicylic acid 167 mg per 1 gram Duofilm paint | 15 ml p £2.78 DT = £2.78 ▶Salactol (Dermal Laboratories Ltd) Lactic acid 167 mg per 1 gram, Salicylic acid 167 mg per 1 gram Salactol paint | 10 ml p £1.71 DT = £1.71 Gel CAUTIONARY AND ADVISORY LABELS 15 ▶Salatac (Dermal Laboratories Ltd) Lactic acid 40 mg per 1 gram, Salicylic acid 120 mg per 1 gram Salatac gel | 8 gram p £2.98 DT = £2.98 Chapter 14 Vaccines CONTENTS Immunoglobulin therapy page 1354 Post-exposure prophylaxis Immunoglobulin therapy IMMUNE SERA AND IMMUNOGLOBULINS › IMMUNOGLOBULINS Vaccines Immunoglobulins Passive immunity Immunity with immediate protection against certain infective organisms can be obtained by injecting preparations made from the plasma of immune individuals with adequate levels of antibody to the disease for which protection is sought. The duration of this passive immunity varies according to the dose and the type of immunoglobulin. Passive immunity may last only a few weeks; when necessary, passive immunisation can be repeated. Antibodies of human origin are usually termed immunoglobulins. The term antiserum is applied to material prepared in animals. Because of serum sickness and other allergic-type reactions that may follow injections of antisera, this therapy has been replaced wherever possible by the use of immunoglobulins. Reactions are theoretically possible after injection of human immunoglobulins but reports of such reactions are very rare. Two types of human immunoglobulin preparation are available, normal immunoglobulin p. 1358 and disease- specific immunoglobulins. Human immunoglobulin is a sterile preparation of concentrated antibodies (immune globulins) recovered from pooled human plasma or serum obtained from outside the UK, tested and found non-reactive for hepatitis B surface antigen and for antibodies against hepatitis C virus and human immunodeficiency virus (types 1 and 2). A global shortage of human immunoglobulin and the rapidly increasing range of clinical indications for treatment with immunoglobulins has resulted in the need for a Demand Management programme in the UK, for further information consult www.ivig.nhs.uk and Clinical Guidelines for Immunoglobulin Use, www.gov.uk/dh. Further information on the use of immunoglobulins is included in Public Health England’s Immunoglobulin Handbook, www.gov.uk/phe, and in the Department of Health’s publication, Immunisation against Infectious Disease, www.gov.uk/dh. Availability Normal immunoglobulin for intramuscular administration is available from some regional Public Health laboratories for protection of contacts and the control of outbreaks of hepatitis A, measles, and rubella only. For other indications, subcutaneous or intravenous normal immunoglobulin should be purchased from the manufacturer. Disease-specific immunoglobulins are available from some regional Public Health laboratories, with the exception of tetanus immunoglobulin p. 1360 which is available from Tuberculosis diagnostic test page 1361 Vaccination BPL, hospital pharmacies, or blood transfusion departments. Rabies immunoglobulin p. 1359 is available from the Specialist and Reference Microbiology Division, Public Health England, Colindale. Hepatitis B immunoglobulin p. 1357 required by transplant centres should be obtained commercially. In Scotland all immunoglobulins are available from the Scottish National Blood Transfusion Service (SNBTS). In Wales all immunoglobulins are available from the Welsh Blood Service (WBS). In Northern Ireland all immunoglobulins are available from the Northern Ireland Blood Transfusion Service (NIBTS). Normal immunoglobulin Human normal immunoglobulin (‘HNIG’) is prepared from pools of at least 1000 donations of human plasma; it contains immunoglobulin G (IgG) and antibodies to hepatitis A, measles, mumps, rubella, varicella, and other viruses that are currently prevalent in the general population. Uses Normal immunoglobulin (containing 10%–18% protein) is administered by intramuscular injection for the protection of susceptible contacts against hepatitis A virus (infectious hepatitis), measles and, to a lesser extent, rubella. Injection of immunoglobulin produces immediate protection lasting several weeks. Normal immunoglobulin (containing 3%–12% protein) for intravenous administration is used as replacement therapy for patients with congenital agammaglobulinaemia and hypogammaglobulinaemia, and for the short-term treatment of idiopathic thrombocytopenic purpura and Kawasaki disease; it is also used for the prophylaxis of infection following bone-marrow transplantation and in children with symptomatic HIV infection who have recurrent bacterial infections. Normal immunoglobulin for replacement therapy may also be given intramuscularly or subcutaneously, but intravenous formulations are normally preferred. Intravenous immunoglobulin is also used in the treatment of Guillain-Barré syndrome as an alternative to plasma exchange. For guidance on the use of intravenous normal immunoglobulin and alternative therapies for certain conditions, consult Clinical Guidelines for Immunoglobulin Use (www.gov.uk/dh). Hepatitis A Hepatitis A vaccine p. 1388 is recommended for individuals at risk of infection including those visiting areas where the disease is highly endemic (all countries excluding Northern and Western Europe, North America, Japan, Australia, and New Zealand). In unimmunised individuals, transmission of hepatitis A is reduced by good hygiene. Intramuscular normal immunoglobulin is no longer recommended for prophylaxis in travellers. Public Health England recommends the use of normal immunoglobulin in addition to hepatitis A vaccine for prevention of infection in close contacts (of confirmed cases of hepatitis A) who are 60 years of age or over, have chronic liver disease (including chronic hepatitis B or C infection), or HIV infection (with a CD4 count < 200 cells per microlitre), or who are immunosuppressed; normal immunoglobulin should be given as soon as possible, preferably within 14 days of exposure to the primary case. However, normal immunoglobulin can still be given to contacts with chronic liver disease up to 28 days after exposure to the primary case. Hepatitis A vaccine can be given at the same time, but it should be given at a separate injection site. Measles Intravenous or subcutaneous normal immunoglobulin may be given to prevent or attenuate an attack of measles in individuals who do not have adequate immunity. Patients with compromised immunity who have come into contact with measles should receive intravenous or subcutaneous normal immunoglobulin as soon as possible after exposure. It is most effective if given within 72 hours but can be effective if given within 6 days. Subcutaneous or intramuscular normal immunoglobulin should also be considered for the following individuals if they have been in contact with a confirmed case of measles or with a person associated with a local outbreak: . non-immune pregnant women . infants under 9 months Further advice should be sought from the Centre for Infections, Public Health England (tel. (020) 8200 6868). Individuals with normal immunity who are not in the above categories and who have not been fully immunised against measles, can be given measles, mumps and rubella vaccine, live p. 1393 for prophylaxis following exposure to measles. Rubella Intramuscular immunoglobulin after exposure to rubella does not prevent infection in non-immune contacts and is not recommended for protection of pregnant women exposed to rubella. It may, however, reduce the likelihood of a clinical attack which may possibly reduce the risk to the fetus. Risk of intra-uterine transmission is greatest in the first 11 weeks of pregnancy, between 16 and 20 weeks there is minimal risk of deafness only, after 20 weeks there is no increased risk. Intramuscular normal immunoglobulin should be used only if termination of pregnancy would be unacceptable to the pregnant woman—it should be given as soon as possible after exposure. Serological follow-up of recipients is essential to determine if the woman has become infected despite receiving immunoglobulin. For routine prophylaxis against Rubella, see measles, mumps and rubella vaccine, live p. 1393. Disease-specific immunoglobulins Specific immunoglobulins are prepared by pooling the plasma of selected human donors with high levels of the specific antibody required. For further information, see Immunoglobulin Handbook (www.gov.uk/phe). There are no specific immunoglobulins for hepatitis A, measles, or rubella— normal immunoglobulin p. 1358 is used in certain circumstances. There is no specific immunoglobulin for mumps; neither normal immunoglobulin nor measles, mumps and rubella vaccine, live is effective as post-exposure prophylaxis. Hepatitis B immunoglobulin Disease-specific hepatitis B immunoglobulin p. 1357 (‘HBIG’) is available for use in association with hepatitis B vaccine p. 1389 for the prevention of infection in laboratory and other personnel who have been accidentally inoculated with hepatitis B virus, and in infants born to mothers who have become infected with this virus in pregnancy or who are high-risk carriers. Hepatitis B immunoglobulin will not inhibit the antibody response when given at the same time as hepatitis B vaccine but should be given at different sites. An intravenous and subcutaneous preparation of hepatitis B immunoglobulin is licensed for the prevention of hepatitis B recurrence in HBV-DNA negative patients who have undergone liver transplantation for liver failure caused by the virus. Rabies immunoglobulin Following exposure of an unimmunised individual to an animal in or from a country where the risk of rabies is high the site of the bite should be washed with soapy water and specific rabies immunoglobulin p. 1359 of human origin administered. All of the dose should be injected around the site of the wound; if this is difficult or the wound has completely healed it can be given in the anterolateral thigh (remote from the site used for vaccination). Rabies vaccine p. 1394 should also be given intramuscularly at a different site (for details see rabies vaccine). If there is delay in giving the rabies immunoglobulin, it should be given within 7 days of starting the course of rabies vaccine. Tetanus immunoglobulin Vaccines For the management of tetanus-prone wounds, tetanus immunoglobulin p. 1360 should be used in addition to wound cleansing and, where appropriate, antibacterial prophylaxis and a tetanus-containing vaccine. Tetanus immunoglobulin, together with metronidazole p. 572 and wound cleansing, should also be used for the treatment of established cases of tetanus. Varicella–zoster immunoglobulin Varicella-zoster immunoglobulin p. 1360 (VZIG) is recommended for individuals who are at increased risk of severe varicella (neonates, pregnant women and immunosuppressed individuals with varicella-zoster virus immunoglobulin G antibody less than 150 mIU/mL) and who have no antibodies to varicella–zoster virus and who have significant exposure to chickenpox (varicella) or shingles (herpes zoster) during the infectious period. Immunosuppressed patients receiving regular intravenous immunoglobulin replacement therapy only require varicella- zoster immunoglobulin if the most recent dose was administered more than 3 weeks before exposure. Immunosuppressed patients on long term aciclovir p. 670 or valaciclovir p. 673 prophylaxis will require a temporary increase in their dose following exposure; for patients within 12 months of a stem cell transplant, varicella-zoster immunoglobulin should also be considered. Important: for full details consult Guidance for issuing varicella-zoster immunoglobulin (VZIG) and Immunisation against infectious disease from Public Health England (www.gov.uk). Anti-D (Rh0) immunoglobulin Anti-D (Rh0) immunoglobulin p. 1356 is prepared from plasma taken from rhesus-negative donors who have been immunised against the anti-D-antigen. Anti-D (Rh0) immunoglobulin is used to prevent a rhesus-negative mother from forming antibodies to fetal rhesus-positive cells which may pass into the maternal circulation. The objective is to protect any subsequent child from the hazard of haemolytic disease of the newborn. Anti-D (Rh0) immunoglobulin should be administered to the mother following any sensitising episode (e.g. abortion, miscarriage and birth); it should be injected within 72 hours of the episode but even if a longer period has elapsed it may still give protection and should be administered. Anti-D (Rh0) immunoglobulin is also given when significant feto- maternal haemorrhage occurs in rhesus-negative women during delivery. The dose of anti-D (Rh0) immunoglobulin is determined according to the level of exposure to rhesus- positive blood. Use of routine antenatal anti-D prophylaxis should be given irrespective of previous anti-D prophylaxis for a sensitising event early in the same pregnancy. Similarly, postpartum anti-D prophylaxis should be given irrespective of previous routine antenatal anti-D prophylaxis or antenatal anti-D prophylaxis for a sensitising event in the same pregnancy. Anti-D (Rh0) immunoglobulin is also given to women of child-bearing potential after the inadvertent transfusion of rhesus-incompatible blood components and is used for the treatment of idiopathic thrombocytopenia purpura. MMR vaccine Measles, mumps and rubella vaccine, live may be given in the postpartum period with anti-D (Rh0) immunoglobulin injection provided that separate syringes are used and the products are administered into different limbs. If blood is transfused, the antibody response to the vaccine may be inhibited—measure rubella antibodies after 6–8 weeks and revaccinate if necessary.
PDF pages 1375, 1376, 1377, 1378
Apply daily, treatment may need to be
First-line fragment. Read the complete Indications and Dose section above.
PDF page 1375
Apply daily, treatment may need to be
First-line fragment. Read the complete Indications and Dose section above.
PDF page 1375
Apply daily, treatment may need to be
First-line fragment. Read the complete Indications and Dose section above.
PDF page 1375
